The Stemness Phenotype Model

Table 1

Detection of CSCs in established breast cancer cell lines.

Cell line	Percentage	Method	Reference
BT-474	0.5%	SP (H33342 labeling)	[16]
EFM-19	0.3%	SP (H33342 labeling)	[16]
KPL-1	8.4%	SP (H33342 labeling)	[16]
MCF-7	0.8%	SP (H33342 labeling)	[16]
UACC-893	20%	SP (H33342 labeling)	[16]
BT-20	5.8%	SP (H33342 labeling)	[16]
Cal-51	0.8–2%	SP (H33342 labeling)	[16]
MCF-7	2.4 ± 0.4%	SP (H33342 labeling)	[17]
MCF-7	1.5%	SP (H33342 labeling)	[18]
T47D,	0%	SP (H33342 labeling)	[17]
SK-BR-3	0%	SP (H33342 labeling)	[17]
MDA-MB-231	0%	SP (H33342 labeling)	[17]
MDA-MB-231	0.1%	SP (H33342 labeling)	[18]
MDA-MB-231	>90%	CD44^pos/CD24^neg/low (flow cytometry)	[19]
MCF-7	1.6% (monolayer cultures); 40.3% (mammospheres)	CD44^pos/CD24^neg/low (flow cytometry)	[20]
MCF-7	<2% (monolayer cultures) ~50% (mammospheres)	CD44^pos/CD24^neg/low (flow cytometry)	[21]
MCF-7	3.5%	SP (H33342 labeling)	[22]